Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

Synthesis and Anticancer Activity of Oral Pt(IV) Prodrugs Containing α-furancarboxylate as an Axial Ligand

Author(s): Anli Gao, Peng Zhou, Juan Yu, Min Luo, Jing Jiang*, Ling Zhang, Weiping Liu* and Chen Qing*

Volume 21, Issue 13, 2024

Published on: 20 October, 2023

Page: [2751 - 2759] Pages: 9

DOI: 10.2174/0115701808257585231016055814

Price: $65

Abstract

Background: The clinical applications of platinum-based anticancer drugs are largely compromised by side effects and drug resistance. Therefore, novel platinum-based anticancer drugs with improved injected or oral therapeutic index and low resistance need to be developed.

Objective: This study aimed at the synthesis and anticancer activity testing of Pt(IV) prodrugs containing α-furancarboxylate as an axial ligand. This would pave the way for obtaining novel Pt(IV) prodrugs with better anticancer activity by comparing the anticancer activity with their parent platinum( II) complexes.

Methods: In this study, synthesis, in vitro cytoxicity assay, and in vivo anticancer activity evaluation of three Pt(IV) complexes, cis,trans,cis-[Pt(NH3)2(OH)(α-furancarboxylato)Cl2] (FPt-1), cis,trans,cis- [Pt(NH3)2(OH)(α-furancarboxylato)(1,1'-cylobutanedicarboxylato)] (FPt-2), and cis,trans,cis- [Pt(1R,2R-diaminocyclohexane)(OH)(α-furancarboxylato)(C2O4)] (FPt-3), were carried out.

Results: Three Pt(IV) complexes exhibited considerable cytoxicity against the tested human cancer cells (MCF-7, A549 and HCT116), which was found to be slightly lower than the corresponding Pt(II) drugs. However, FPt-1 and FPt-3 displayed comparable antitumor efficacy to cisplatin and oxaliplatin in the murine S180 sarcoma model after intraperitoneal administration. More importantly, the intragastric administration test indicated the antitumor efficacy of FPt-3 to be much greater than oxaliplatin.

Conclusion: FPt-3 has shown excellent oral antitumor activity and it could be administrated in an oral dosage form.

Keywords: Pt(IV) prodrug, oral antitumor activity, anticancer activity, cytotoxicity, synthesis, α-furancarboxylic acid.

« Previous Next »
Graphical Abstract

[1]
Liu, X.M.; Li, Z.; He, X.R.; Liu, R.P.; Ma, Z.Y.; Qiao, X.; Wang, S.Q.; Xu, J.Y. Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt(IV) prodrugs: A new treatment for postmenopausal breast cancer. Inorg. Chem. Front., 2022, 9(14), 3470-3483.
[http://dx.doi.org/10.1039/D2QI00900E]
[2]
Li, Z.; Xu, Q.; Lin, X.; Yu, K.; Lin, L.; Liu, Y.; Yu, Z.; Liu, T.; Luo, D. Integrating of lipophilic platinum(IV) prodrug into liposomes for cancer therapy on patient-derived xenograft model. Chin. Chem. Lett., 2022, 33(4), 1875-1879.
[http://dx.doi.org/10.1016/j.cclet.2021.10.077]
[3]
Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
[http://dx.doi.org/10.1038/nrc2167] [PMID: 17625587]
[4]
Ma, L.; Li, L.; Zhu, G. Platinum-containing heterometallic complexes in cancer therapy: Advances and perspectives. Inorg. Chem. Front., 2022, 9(11), 2424-2453.
[http://dx.doi.org/10.1039/D2QI00205A]
[5]
Kostova, I. Platinum complexes as anticancer agents. Recent Patents Anticancer Drug Discov., 2006, 1(1), 1-22.
[http://dx.doi.org/10.2174/157489206775246458] [PMID: 18221023]
[6]
Urien, S.; Brain, E.; Bugat, R.; Pivot, X.; Lochon, I.; Van, M.L.V.; Vauzelle, F.; Lokiec, F. Pharmacokinetics of platinum after oral or intravenous cisplatin: A phase 1 study in 32 adult patients. Cancer Chemother. Pharmacol., 2005, 55(1), 55-60.
[http://dx.doi.org/10.1007/s00280-004-0852-8] [PMID: 15258698]
[7]
Oehlsen, M.E.; Qu, Y.; Farrell, N. Reaction of polynuclear platinum antitumor compounds with reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum coherence, and 195Pt) NMR spectroscopy. Inorg. Chem., 2003, 42(18), 5498-5506.
[http://dx.doi.org/10.1021/ic030045b] [PMID: 12950196]
[8]
Yan, J.; Zhang, Y.; Zheng, L.; Wu, Y.; Wang, T.; Jiang, T.; Liu, X.; Peng, D.; Liu, Y.; Liu, Z. Let‐7i miRNA and platinum loaded nano‐graphene oxide platform for detection/reversion of drug resistance and synergetic chemical‐photothermal inhibition of cancer cell. Chin. Chem. Lett., 2022, 33(2), 767-772.
[http://dx.doi.org/10.1016/j.cclet.2021.08.018]
[9]
Zhou, J.; Kang, Y.; Chen, L.; Wang, H.; Liu, J.; Zeng, S.; Yu, L. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol., 2020, 11, 343-359.
[http://dx.doi.org/10.3389/fphar.2020.00343] [PMID: 32265714]
[10]
Zhong, Y.; Jia, C.; Zhang, X.; Liao, X.; Yang, B.; Cong, Y.; Pu, S.; Gao, C. Targeting drug delivery system for platinum(IV)-Based antitumor complexes. Eur. J. Med. Chem., 2020, 194, 112229.
[http://dx.doi.org/10.1016/j.ejmech.2020.112229] [PMID: 32222677]
[11]
Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. Third row transition metals for the treatment of cancer. Philos. Trans. R Soc. A, 2015, 373, 20140185.
[12]
Jalili, S.; Maddah, M.; Schofield, J. Molecular dynamics simulation and free energy analysis of the interaction of platinum-based anti-cancer drugs with DNA. J. Theor. Comput. Chem., 2016, 15(6), 1650054.
[http://dx.doi.org/10.1142/S0219633616500541]
[13]
Zhao, C.L.; Qiao, X.; Liu, X.M.; Song, X.Q.; Zou, Y.H.; Li, D.Q.; Yu, X.W.; Bao, W.G.; Xu, J.Y. Rapid DNA interstrand cross-linking of Pt(IV) compound. Eur. J. Pharmacol., 2022, 925, 174985.
[http://dx.doi.org/10.1016/j.ejphar.2022.174985] [PMID: 35489419]
[14]
Najjar, A.; Rajabi, N.; Karaman, R. Recent approaches to platinum(IV) prodrugs: A variety of strategies for enhanced delivery and efficacy. Curr. Pharm. Des., 2017, 23(16), 2366-2376.
[http://dx.doi.org/10.2174/1381612823666170201161037] [PMID: 28155621]
[15]
Deng, Z.; Wang, N.; Liu, Y.; Xu, Z.; Wang, Z.; Lau, T.C.; Zhu, G. A photocaged, water-oxidizing, and nucleolus-targeted Pt(IV) complex with a distinct anticancer mechanism. J. Am. Chem. Soc., 2020, 142(17), 7803-7812.
[http://dx.doi.org/10.1021/jacs.0c00221] [PMID: 32216337]
[16]
Kasparkova, J.; Kostrhunova, H.; Novakova, O.; Křikavová, R.; Vančo, J.; Trávníček, Z.; Brabec, V. A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew. Chem. Int. Ed., 2015, 54(48), 14478-14482.
[http://dx.doi.org/10.1002/anie.201506533] [PMID: 26458068]
[17]
Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev., 2016, 116(5), 3436-3486.
[http://dx.doi.org/10.1021/acs.chemrev.5b00597] [PMID: 26865551]
[18]
Wilson, J.J.; Lippard, S.J. Synthetic methods for the preparation of platinum anticancer complexes. Chem. Rev., 2014, 114(8), 4470-4495.
[http://dx.doi.org/10.1021/cr4004314] [PMID: 24283498]
[19]
Kenny, R.G.; Marmion, C.J. Toward multi-targeted platinum and ruthenium drugs: A new paradigm in cancer drug treatment regimens. Chem. Rev., 2019, 119(2), 1058-1137.
[http://dx.doi.org/10.1021/acs.chemrev.8b00271] [PMID: 30640441]
[20]
Shi, Y.; Liu, S.A.; Kerwood, D.J.; Goodisman, J.; Dabrowiak, J.C. Pt(IV) complexes as prodrugs for cisplatin. J. Inorg. Biochem., 2012, 107(1), 6-14.
[http://dx.doi.org/10.1016/j.jinorgbio.2011.10.012] [PMID: 22169035]
[21]
Tolan, D.; Gandin, V.; Morrison, L.; El-Nahas, A.; Marzano, C.; Montagner, D.; Erxleben, A. Oxidative stress induced by Pt(IV) pro-drugs based on the cisplatin scaffold and indole carboxylic acids in axial position. Sci. Rep., 2016, 6(1), 29367.
[http://dx.doi.org/10.1038/srep29367] [PMID: 27404565]
[22]
Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) pro-drugs? J. Inorg. Biochem., 2012, 117, 220-229.
[http://dx.doi.org/10.1016/j.jinorgbio.2012.06.013] [PMID: 22877926]
[23]
Wexselblatt, E.; Yavin, E.; Gibson, D. Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions. Angew. Chem. Int. Ed., 2013, 52(23), 6059-6062.
[http://dx.doi.org/10.1002/anie.201300640] [PMID: 23686723]
[24]
Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci., 2008, 105(45), 17356-17361.
[http://dx.doi.org/10.1073/pnas.0809154105] [PMID: 18978032]
[25]
Dhar, S.; Kolishetti, N.; Lippard, S.J.; Farokhzad, O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci., 2011, 108(5), 1850-1855.
[http://dx.doi.org/10.1073/pnas.1011379108] [PMID: 21233423]
[26]
Hambley, T.W.; Battle, A.R.; Deacon, G.B.; Lawrenz, E.T.; Fallon, G.D.; Gatehouse, B.M.; Webster, L.K.; Rainone, S. Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness. J. Inorg. Biochem., 1999, 77(1-2), 3-12.
[http://dx.doi.org/10.1016/S0162-0134(99)00133-6] [PMID: 10626347]
[27]
Reithofer, M.R.; Bytzek, A.K.; Valiahdi, S.M.; Kowol, C.R.; Groessl, M.; Hartinger, C.G.; Jakupec, M.A.; Galanski, M.S.; Keppler, B.K. Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J. Inorg. Biochem., 2011, 105(1), 46-51.
[http://dx.doi.org/10.1016/j.jinorgbio.2010.09.006] [PMID: 21134601]
[28]
Mi, Q.; Shu, S.; Yang, C.; Gao, C.; Zhang, X.; Luo, X.; Bao, C.; Zhang, X.; Niu, J. Current status for oral platinum (IV) anticancer drug development. Int. J. Med. Phys. Clin. Eng. Radiat. Oncol., 2018, 7(2), 231-247.
[http://dx.doi.org/10.4236/ijmpcero.2018.72020]
[29]
Harstrick, A.; Casper, J.; Guba, R.; Wilke, H.; Poliwoda, H.; Schmoll, H.J. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer, 1989, 63, 1079-1083.
[30]
Bednarski, P.J.; Mackay, F.S.; Sadler, P.J. Photoactivatable platinum complexes. Anticancer. Agents Med. Chem., 2007, 7(1), 75-93.
[http://dx.doi.org/10.2174/187152007779314053] [PMID: 17266506]
[31]
Braddock, P.D.; Connors, T.A.; Jones, M.; Khokhar, A.R.; Melzack, D.H.; Tobe, M.L. Structure and activity relationships of platinum complexes with anti-tumour activity. Chem. Biol. Interact., 1975, 11(3), 145-161.
[http://dx.doi.org/10.1016/0009-2797(75)90095-2] [PMID: 1157188]
[32]
Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer, 1998, 34(10), 1522-1534.
[http://dx.doi.org/10.1016/S0959-8049(98)00224-X] [PMID: 9893623]
[33]
Choy, H.; Park, C.; Yao, M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin. Cancer Res., 2008, 14(6), 1633-1638.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-2176] [PMID: 18347164]
[34]
Doshi, G.; Sonpavde, G.; Sternberg, C.N. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin. Drug Metab. Toxicol., 2012, 8(1), 103-111.
[http://dx.doi.org/10.1517/17425255.2012.636352] [PMID: 22098065]
[35]
Žák, F.; Turánek, J.; Kroutil, A.; Sova, P.; Mistr, A.; Poulová, A.; Mikolin, P.; Žák, Z.; Kašná, A.; Záluská, D.; Neča, J.; Šindlerová, L.; Kozubík, A. Platinum(IV) complex with adamantylamine as nonleaving amine group: Synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J. Med. Chem., 2004, 47(3), 761-763.
[http://dx.doi.org/10.1021/jm030858+] [PMID: 14736257]
[36]
Sova, P.; Mistr, A.; Kroutil, A.; Zak, F.; Pouckova, P.; Zadinova, M. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anticancer Drugs, 2005, 16(6), 653-657.
[http://dx.doi.org/10.1097/00001813-200507000-00010] [PMID: 15930894]
[37]
Fadzen, C.M.; Wolfe, J.M.; Zhou, W.; Cho, C.F.; von Spreckelsen, N.; Hutchinson, K.T.; Lee, Y.C.; Chiocca, E.A.; Lawler, S.E.; Yilmaz, O.H.; Lippard, S.J.; Pentelute, B.L. A platinum(IV) prodrug-perfluoroaryl macrocyclic peptide conjugate enhances platinum uptake in the brain. J. Med. Chem., 2020, 63(13), 6741-6747.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00022] [PMID: 32410451]
[38]
Novohradsky, V.; Pracharova, J.; Kasparkova, J.; Imberti, C.; Bridgewater, H.E.; Sadler, P.J.; Brabec, V. Induction of immunogenic cell death in cancer cells by a photoactivated platinum(IV) prodrug. Inorg. Chem. Front., 2020, 7(21), 4150-4159.
[http://dx.doi.org/10.1039/D0QI00991A] [PMID: 34540235]
[39]
Yang, T.; Zhang, S.R.; Yuan, H.; Wang, Y.; Cai, L.X.; Chen, H.H.; Wang, X.Y.; Song, D.F.; Wang, X.Y. Platinum-based TREM2 inhibitor suppresses tumors by remodeling the immune suppressive microenvironment. Angew. Chem. Int. Ed., 2023, 62, e202213337.
[http://dx.doi.org/10.1002/anie.202213337] [PMID: 36259513]
[40]
Yuan, S.; Zhu, Y.; Dai, Y.; Wang, Y.; Jin, D.; Liu, M.; Tang, L.; Arnesano, F.; Natile, G.; Liu, Y. 19F NMR Allows the investigation of the fate of platinum(IV) prodrugs in physiological conditions. Angew. Chem. Int. Ed., 2022, 61(4), e202114250.
[http://dx.doi.org/10.1002/anie.202114250] [PMID: 34800083]
[41]
Chen, F.; Xu, G.; Tian, W.; Gou, S. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability. Biochem. Pharmacol., 2021, 193, 114785.
[http://dx.doi.org/10.1016/j.bcp.2021.114785] [PMID: 34562469]
[42]
Xu, Z.; Wang, Z.; Deng, Z.; Zhu, G. Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs. Coord. Chem. Rev., 2021, 442, 213991.
[http://dx.doi.org/10.1016/j.ccr.2021.213991]
[43]
Sedaghat, T.; Ebrahimi, Y.; Carlucci, L.; Proserpio, D.M.; Nobakht, V.; Motamedi, H.; Dayer, M.R. Diorganotin(IV) complexes with 2-furancarboxylic acid hydrazone derivative of benzoylacetone: Synthesis, X-ray structure, antibacterial activity, DNA cleavage and molecular docking. J. Organomet. Chem., 2015, 794, 223-230.
[http://dx.doi.org/10.1016/j.jorganchem.2015.06.034]
[44]
Gilmore, C.J.; Mallinson, P.R.; Speakman, J.C. Structure of 2-furoic acid, C5H4O3: A redetermination. Acta Crystallogr. C, 1983, 39(8), 1111-1113.
[http://dx.doi.org/10.1107/S010827018300757X]
[45]
Nikiforova, M.E.; Lutsenko, I.A.; Kiskin, M.A.; Nelyubina, Y.V.; Primakov, P.V.; Bekker, O.B.; Khoroshilov, A.V.; Eremenko, I.L. Coordination polymer of Ba2+ with 2-furoic acid anions: Synthesis, structure, and thermal properties. Russ. J. Inorg. Chem., 2021, 66(9), 1343-1349.
[http://dx.doi.org/10.1134/S0036023621090102]
[46]
Varbanov, H.P.; Valiahdi, S.M.; Kowol, C.R.; Jakupec, M.A.; Galanski, M.S.; Keppler, B.K. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. Dalton Trans., 2012, 41(47), 14404-14415.
[http://dx.doi.org/10.1039/C2DT31366A] [PMID: 22886297]
[47]
Harrap, K.R.; Murrer, B.A.; Giandomenico, C.; Morgan, S.E.; Kelland, L.R.; Jones, M.; Goddard, P.M.; Schurig, J. Ammine/amine platinum IV dicarboxylates: A novel class of complexes which circumvent intrinsic cisplatin resistance. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy; Plenum Press: New York, 1991; pp. 391-399.
[http://dx.doi.org/10.1007/978-1-4899-0738-7_36]

Rights & Permissions Print Cite
Article Metrics
18
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy